BLA 125160 · Ucb INC
Cimzia
Certolizumab Pegol · Injection · Tumor Necrosis Factor Blocker
NovelLast checked: Nov 20, 2026Latest source record: Sep 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Apr 22, 2008
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
119
62 Phase 3, 10 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Certolizumab Pegol" as an intervention, any sponsor and status, largest first.
- Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid ArthritisPivotal-lookingCompleted
UCB PharmaUCB
NCT00717236 · 1,648 participants · Start Jul 2008 · Primary completion Mar 2010
Drug: Certolizumab pegol (CZP) · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Montgomery, Alabama; Phoenix, Arizona · 181 sites in all
- A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid ArthritisPivotal-lookingCompleted
UCB PharmaUCB
NCT00152386 · 950 participants · Start Feb 2005 · Primary completion Oct 2006
Drug: Certolizumab pegol (CDP870) · For: Rheumatoid Arthritis
Sites: Huntsville, Alabama; Paradise Valley, Arizona; La Jolla, California · 76 sites in all
NCT01500278 · 915 participants · Start Dec 2011 · Primary completion Nov 2015
Drug: Certolizumab Pegol (CZP); Adalimumab (ADA) and 1 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Tuscaloosa, Alabama; Tucson, Arizona · 175 sites in all
NCT01519791 · 880 participants · Start Jan 2012 · Primary completion Jul 2014
Drug: Certolizumab Pegol; Methotrexate · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 178 sites in all
- A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid ArthritisPivotal-lookingCompleted
UCB PharmaUCB
NCT00175877 · 857 participants · Start Jun 2005 · Primary completion Feb 2012
Drug: Certolizumab Pegol · For: Rheumatoid Arthritis
Sites: Huntsville, Alabama; San Diego, California; Danbury, Connecticut · 121 sites in all
- COVID-19 VaccinE Response in Rheumatology PatientsPivotal-lookingCompleted
Jeffrey CurtisAcademic, hospital or other
NCT05080218 · 841 participants · Start Nov 15, 2021 · Primary completion Apr 4, 2024
Drug: Upadacitinib; Abatacept and 6 more · For: Rheumatoid Arthritis; Psoriatic Arthritis; Spondylarthritis
Sites: Birmingham, Alabama; Hoover, Alabama; Phoenix, Arizona · 8 sites in all
- Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose ReductionPivotal-lookingStatus unknown
Karolinska InstitutetAcademic, hospital or other
NCT01491815 · 812 participants · Start Dec 14, 2012 · Primary completion Jul 2023
Drug: Non-biological DMARD's; Cimzia and 2 more · For: Rheumatoid Arthritis
Sites: Aalborg, Denmark; Aarhus, Denmark; Copenhagen, Denmark · 30 sites in all
- A Comparison of Two Assessment Tools in Predicting Treatment Success of Cimzia in Rheumatoid Arthritis SubjectsPivotal-lookingCompleted
UCB PharmaUCB
NCT01255761 · 736 participants · Start Nov 2010 · Primary completion Oct 2012
Drug: Certolizumab Pegol (CZP) · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Peoria, Arizona · 110 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cimzia (Certolizumab PEGol)
2024 spending
$19.6M
Beneficiaries
1,116
1,162 claims
Per beneficiary
$17,535
$5,631.50 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $14,284,959 |
| 2021 | $16,650,567 |
| 2022 | $17,362,726 |
| 2023 | $18,293,307 |
| 2024 | $19,569,457 |
Part B: Cimzia* (Certolizumab Pegol*) · HCPCS J0717
2024 spending
$398M
Beneficiaries
25,557
222,693 claims
Per beneficiary
$15,559
2024 ASP limit $4.64 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $508,507,632 |
| 2021 | $500,152,675 |
| 2022 | $431,810,728 |
| 2023 | $401,173,239 |
| 2024 | $397,650,916 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S, Murad MH, Fumery M, et al. · Lancet Gastroenterol Hepatol 2021 · Comparative Study, Research Support, N.I.H., Extramural
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Ferreira RJO, et al. · Ann Rheum Dis 2024 · Systematic Review
- Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis.
Singh S, Murad MH, Yuan Y, et al. · Gastroenterology 2025 · Systematic Review, Comparative Study
- Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.
Østergaard M, van Vollenhoven RF, Rudin A, et al. · Ann Rheum Dis 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Kerschbaumer A, Sepriano A, Bergstra SA, et al. · Ann Rheum Dis 2023 · Systematic Review, Research Support, Non-U.S. Gov't
- Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review.
van Gendt J, Emaus R, Visschedijk MC, et al. · Clin Pharmacokinet 2024 · Systematic Review
Sponsor: UCB
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.